This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Abrams RA , Winter KA , Regine WF , Safran H , Hoffman JP , Lustig R , Konski AA , Benson AB , Macdonald JS , Rich TA , Willett CG
FAILURE TO ADHERE TO PROTOCOL SPECIFIED RADIATION THERAPY GUIDELINES WAS ASSOCIATED WITH DECREASED SURVIVAL IN RTOG 9704-A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AND CHEMORADIOTHERAPY FOR PATIENTS WITH RESECTED ADENOCARCINOMA OF THE PANCREAS
International Journal of Radiation Oncology Biology Physics. 2012 Feb;82(2) :809-816
PMID: WOS:000299239900054 PMCID: PMC133855
AbstractPurpose: In Radiation Therapy Oncology Group 9704, as previously published, patients with resected pancreatic adenocarcinoma received continuous infusion 5-FU and concurrent radiotherapy (5FU-RT). 5FU-RT treatment was preceded and followed by randomly assigned chemotherapy, either 5-FU or gemcitabine. This analysis explored whether failure to adhere to specified RT guidelines influenced survival and/or toxicity. Methods and Materials: RT requirements were protocol specified. Adherence was scored as per protocol (PP) or less than per protocol (<PP). Scoring occurred after therapy but before trial analysis and without knowledge of individual patient treatment outcomes. Scoring was done for all tumor locations and for the subset of pancreatic head location. Results: RT was scored for 416 patients: 216 PP and 200 <PP. For all pancreatic sites (head, body/tail) median survival (MS) for PP vs. <PP was 1.74 vs. 1.46 years (log rank p = 0.0077). In multivariate analysis, PP vs. <PP score correlated more strongly with MS than assigned treatment arm (p = 0.014,p = NS, respectively); for patients with pancreatic head tumors, both PP score and gemcitabine treatment correlated with improved MS (p = 0.016, p = 0.043, respectively). For all tumor locations, PP score was associated with decreased risk of failure (p = 0.016) and, for gemcitabine patients, a trend toward reduced Grade 4/5 nonhematologic toxicity (p = 0.065). Conclusions: This is the first Phase III, multicenter, adjuvant protocol for pancreatic adenocarcinoma to evaluate the impact of adherence to specified RT protocol guidelines on protocol outcomes. Failure to adhere to specified RT guidelines was associated with reduced survival and, for patients receiving gemcitabine, trend toward increased nonhematologic toxicity. (C) 2012 Elsevier Inc.
NotesAbrams, Ross A. Winter, Kathryn A. Regine, William F. Safran, Howard Hoffman, John P. Lustig, Robert Konski, Andre A. Benson, Al B. Macdonald, John S. Rich, Tyvin A. Willett, Christopher G. Rtog[ca21661, ca37422, 32115] Supported by the following grants for the RTOG: CA21661, CA37422, and 32115 Clinicaltrials.gov Identifier: NCT00003216 40 Elsevier science inc New york 878fc Gnon jp, 1992, new england journal of medicine, v327, p1618